The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Other Relationship - Kite, a Gilead company
End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
 
Bijal D. Shah
Honoraria - Pharmacyclics/Janssen
Consulting or Advisory Role - Adaptive Biotechnologies
Research Funding - Incyte; Jazz Pharmaceuticals (Inst)
 
Michael Russell Bishop
Employment - UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - Seagen
Speakers' Bureau - Celgene; Juno Therapeutics; Novartis
 
Olalekan O. Oluwole
Consulting or Advisory Role - Bayer; Kite, a Gilead company; Pfizer; Spectrum Pharmaceuticals
Research Funding - Kite, a Gilead company
 
Aaron Logan
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Incyte; Jazz Pharmaceuticals
Research Funding - Astellas Pharma; Kite, a Gilead company; Novartis; Pharmacyclics
 
Maria R. Baer
No Relationships to Disclose
 
William Bruce Donnellan
No Relationships to Disclose
 
Kristen Marie Carr-O'Dwyer
No Relationships to Disclose
 
Houston Holmes
Consulting or Advisory Role - Bayer; Gilead Sciences; Rigel
Speakers' Bureau - Gilead Sciences; Seagen
Research Funding - Celgene; Genentech; Gilead Sciences; Novartis; Seagen; Unum
 
Martha Lucia Arellano
Research Funding - Cephalon (Inst)
 
Armin Ghobadi
No Relationships to Disclose
 
John M. Pagel
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
 
Yi Lin
No Relationships to Disclose
 
Ryan Daniel Cassaday
Employment - Seagen (I)
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Pfizer
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Jazz Pharmaceuticals
Research Funding - Amgen (Inst); Gilead Sciences (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen
 
Jae Hong Park
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Kite, a Gilead company; Novartis; Pfizer
Research Funding - Genentech/Roche (Inst); Juno Therapeutics (Inst)
 
Armen Mardiros
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
 
Tong Shen
Employment - Kite, a Gilead company
 
Lovely Goyal
Employment - Kite, a Gilead company
 
Remus Vezan
Employment - Kite, a Gilead company
 
Rajul K. Jain
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Amgen; Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - Kite, a Gilead company
Travel, Accommodations, Expenses - Kite, a Gilead company
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor